Kezar Life Sciences Newsroom

Hold Rating on Kezar Life Sciences Amid Trial Progress and Efficacy Concerns

TipRanksMay 10 06:37 ET

Express News | Kezar Life Sciences Q1 EPS $(0.30) Beats $(0.33) Estimate

BenzingaMay 9 16:40 ET

Kezar Life Sciences | 10-Q: Quarterly report

Futu NewsMay 9 16:16 ET · Announcements

Press Release: Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update -- PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis act

Dow JonesMay 9 16:01 ET

Kezar Life Sciences 1Q Loss/Shr 30c >KZR

Kezar Life Sciences 1Q Loss/Shr 30c >KZR

Dow JonesMay 9 16:01 ET

Express News | Kezar Life Sciences Q1 Operating Expenses USD 23.711 Million

ReutersMay 9 16:01 ET

Express News | Kezar Life Sciences Q1 Net Income USD -21.658 Million

ReutersMay 9 16:01 ET

Express News | Kezar Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersMay 6 16:05 ET

13 Best Penny Stocks to Buy According to Billionaire Ken Griffin

Yahoo FinanceApr 8 17:38 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)

TipRanksMar 25 08:20 ET

Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR

Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR

Dow JonesMar 14 16:06 ET

Express News | Kezar Life Sciences Q4 EPS $(0.44) Misses $(0.38) Estimate

Moomoo 24/7Mar 14 16:04 ET

Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR

Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR

Dow JonesMar 14 16:04 ET

Kezar Life Sciences 4Q Loss/Shr 44c >KZR

Kezar Life Sciences 4Q Loss/Shr 44c >KZR

Dow JonesMar 14 16:01 ET

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the

BusinesswireMar 8 16:05 ET

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief

BusinesswireFeb 28 16:01 ET

Reported Late Monday, Everest Medicines And Kezar Life Sciences Received IND Approval From China's NMPA For The PALIZADE Trial In Lupus Nephritis

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (NASDAQ:KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approve

BenzingaFeb 27 03:13 ET

Everest Medicines and Kezar Life Sciences Receive IND Approval From China NMPA for PALIZADE Trial in Lupus Nephritis

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China's...

PR NewswireFeb 26 18:10 ET

As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits

The lithium market is facing persistent turmoil as spot prices have continuously declined for more than a year. Supply shortages and speculation caused a lithium bubble in 2022, with spot prices reach

BenzingaJan 8 12:20 ET

Analysts' Top Healthcare Picks: DocGo (DCGO), Kezar Life Sciences (KZR)

TipRanksDec 4, 2023 06:30 ET